KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adaptive Biotechnologies (ADPT) Short term Debt (2023 - 2025)

Adaptive Biotechnologies' Short term Debt history spans 3 years, with the latest figure at $4.6 million for Q4 2025.

  • For Q4 2025, Short term Debt rose 436.65% year-over-year to $4.6 million; the TTM value through Dec 2025 reached $4.6 million, up 436.65%, while the annual FY2025 figure was $4.6 million, 436.65% up from the prior year.
  • Short term Debt for Q4 2025 was $4.6 million at Adaptive Biotechnologies, up from $2.4 million in the prior quarter.
  • Across five years, Short term Debt topped out at $4.6 million in Q4 2025 and bottomed at $865000.0 in Q4 2024.
  • The 3-year median for Short term Debt is $2.7 million (2025), against an average of $2.7 million.
  • The largest YoY upside for Short term Debt was 436.65% in 2025 against a maximum downside of 436.65% in 2025.
  • A 3-year view of Short term Debt shows it stood at $3.2 million in 2023, then plummeted by 72.92% to $865000.0 in 2024, then surged by 436.65% to $4.6 million in 2025.
  • Per Business Quant, the three most recent readings for ADPT's Short term Debt are $4.6 million (Q4 2025), $2.4 million (Q3 2025), and $3.1 million (Q2 2025).